An In-Depth Look At Halozyme Therapeutics Inc (HALO)
Halozyme Therapeutics Inc (NASDAQ:HALO) has a beta value of 1.19 and has seen 3.1 million shares traded in the last trading session. The company, currently
Halozyme Therapeutics Inc (NASDAQ:HALO) has a beta value of 1.19 and has seen 3.1 million shares traded in the last trading session. The company, currently
During the last session, Halozyme Therapeutics Inc (NASDAQ:HALO)’s traded shares were 1.83 million, with the beta value of the company hitting 1.19. At the end
In the last trading session, 1.2 million shares of the Halozyme Therapeutics Inc (NASDAQ:HALO) were traded, and its beta was 1.20. Most recently the company’s
In the last trading session, 2.23 million Halozyme Therapeutics Inc (NASDAQ:HALO) shares changed hands as the company’s beta touched 1.14. With the company’s per share
In last trading session, Halozyme Therapeutics Inc (NASDAQ:HALO) saw 3.66 million shares changing hands with its beta currently measuring 1.15. Company’s recent per share price
During the last session, Halozyme Therapeutics Inc (NASDAQ:HALO)’s traded shares were 9.68 million, with the beta value of the company hitting 1.26. At the end
© 2024, Powered by Smart TechOne